
Currently out of the existing stock ratings of Matthew Shea, 12 are a BUY (100%).
Analyst Matthew Shea, currently employed at NEEDHAM, has had 79.17% of price targets met with an average potential upside of 32.29%, reached in 65 days on average.
Matthew Shea has documented 24 price targets and ratings displayed on 4 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on ASTH, Astrana Health at 05-Nov-2026.
Analyst best performing recommendations are on PRVA (PRIVIA HEALTH GROUP).
The best stock recommendation documented was for TOI (ONCOLOGY INSTITUTE) on 3/9/2026. The price target of $5 was fulfilled within 91 days with a profit of $2.27 (83.15%), with a performance score of 9.14.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold Since 11-Aug-2026
$6
$2.57 (74.93%)
$6
1 days ago
(19-Nov-2026)
Buy Since 01-Mar-2026
$7
$3.57 (104.08%)
$6
15 days ago
(05-Nov-2026)
1/2 (50%)
$2.42 (52.84%)
134
Buy Since 02-Mar-2026
$6
$2.57 (74.93%)
$5
3 months 3 days ago
(17-Aug-2026)
1/2 (50%)
$1.42 (31.00%)
113
Buy Since 14-Nov-2016
$6
$2.57 (74.93%)
$5
3 months 4 days ago
(16-Aug-2026)
11/24 (45.83%)
$1.59 (36.05%)
1198
Hold Since 10-Aug-2026
$6
$2.57 (74.93%)
$6.75
3 months 10 days ago
(10-Aug-2026)
1/7 (14.29%)
$1.9 (46.34%)
42
Which stock is Matthew Shea most bullish on?
Which stock is Matthew Shea most reserved on?
What Year was the first public recommendation made by Matthew Shea?